Bingo Drug-Coated Balloon in Real World
Launched by YINYI(LIAONING) BIOTECH CO., LTD. · Jan 15, 2020
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18 or older, regardless of gender;
- • 2. Patients suitable for PCI with paclitaxel drug-coated balloon;
- • 3. Patients able to understand the purpose of this study, provide an informed consent and cooperate with clinical follow-up.
- Exclusion Criteria:
- • General exclusion criteria
- • 1. Contraindications to PCI;
- • 2. In-stent restenosis;
- • 3. Life expectation less than 1 year;
- • 4. Patients not suitable for enrollment considered by investigator.
- Angiographic exclusion criteria:
- 1. Target lesion with the following conditions after pre-dilatation:
- • 1. Residual stenosis larger than 30% ;
- • 2. TIMI flow grade less than 3;
- • 3. Type C-F dissection (NHLBI grade).
About Yinyi(liaoning) Biotech Co., Ltd.
Yinyi (Liaoning) Biotech Co., Ltd. is a leading biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapeutic solutions. With a strong focus on advancing healthcare through cutting-edge biotechnology, the company specializes in the development of biologics and novel drug formulations. Yinyi Biotech is committed to adhering to the highest standards of clinical research and regulatory compliance, ensuring the safety and efficacy of its products. Through strategic collaborations and a robust pipeline, Yinyi Biotech aims to address unmet medical needs and improve patient outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, , China
Hangzhou, Zhejiang, China
Hangzhou, Zhejiang, China
Patients applied
Trial Officials
Jian-an Wang, MD, PhD
Principal Investigator
Second Affiliated Hospital, School of Medicine, Zhejiang University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials